Loncar Cancer Immunotherapy ETF
Loncar Cancer Immunotherapy ETF
Your view on CNCR
Overview
What the company does, where it operates, and who runs it.
About Loncar Cancer Immunotherapy ETF
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Not available
- Headquarters
- DE, US
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Not available
- Headquarters
- DE, US
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Loncar Cancer Immunotherapy ETF, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Loncar Cancer Immunotherapy ETF. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Loncar Cancer Immunotherapy ETF. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Loncar Cancer Immunotherapy ETF. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Loncar Cancer Immunotherapy ETF. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Loncar Cancer Immunotherapy ETF valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Loncar Cancer Immunotherapy ETF, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Loncar Cancer Immunotherapy ETF executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Loncar Cancer Immunotherapy ETF. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Loncar Cancer Immunotherapy ETF. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Loncar Cancer Immunotherapy ETF. Press releases and market coverage, newest first.